Valuation: ACLS THER

Market Cap 797M 698M 643M 595M 1.13B 76.12B 1.15B 7.7B 3.02B 37.38B 2.99B 2.93B 129B P/E 2026 *
-8.8x
P/E 2027 * -7.17x
Enterprise Value 662M 579M 534M 494M 938M 63.18B 953M 6.39B 2.51B 31.02B 2.48B 2.43B 107B EV / Sales 2026 *
116x
EV / Sales 2027 * 126x
Free-Float
97.72%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 16/01/2024
Director of Finance/CFO 39 31/12/2022
President 67 17/11/2024
Director TitleAgeSince
Chairman 56 31/12/2022
Director/Board Member 50 31/08/2014
Director/Board Member 59 31/08/2016
Change 5-day change 1-year change 3-year change Capi.($)
-0.38%-3.44%+71.35%+128.83% 56.71B
+4.91%-0.19%+73.70%+92.14% 51.3B
+1.48%+5.97%+22.59%+495.47% 25.26B
-0.59%-4.68%-16.82%-12.99% 23.65B
+0.81%-0.96%+44.75%-2.11% 18.69B
+2.01%+2.99%+40.72%-24.93% 17.71B
-6.84%+2.18%+203.03%+348.11% 17.7B
-0.42%-5.57%+40.32% - 14.26B
+1.76%+2.24%+29.57%+195.70% 14.1B
Average +0.21%+2.46%+56.58%+152.53% 26.6B
Weighted average by Cap. +0.79%+0.75%+59.08%+145.17%

Financials

2026 *2027 *
Net sales 5.71M 5M 4.61M 4.26M 8.09M 545M 8.23M 55.19M 21.63M 268M 21.45M 20.98M 928M 5.36M 4.69M 4.32M 4M 7.59M 511M 7.72M 51.77M 20.29M 251M 20.12M 19.68M 870M
Net income -84.78M -74.17M -68.4M -63.28M -120M -8.09B -122M -819M -321M -3.97B -318M -311M -13.77B -103M -89.68M -82.7M -76.52M -145M -9.79B -148M -990M -388M -4.81B -385M -377M -16.64B
Net Debt -136M -119M -109M -101M -192M -12.94B -195M -1.31B -514M -6.36B -509M -498M -22.02B -125M -109M -101M -93.23M -177M -11.92B -180M -1.21B -473M -5.85B -469M -459M -20.28B
Logo ACLS THER
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-